Administration of rAAV encoding monoclonal antibodies protects mice challenged with a lethal dose of H3N2 influenza virus and neutralizes H1 and H3 strains

, and the virus-neutralizing activity of the sera against the H1N1 and H3N2 influenza virus strains was assessed. Administration of rAAV-C585, rAAV-MHAA4549A, and rAAV-1G01 conferred 100% protection to mice challenged with a lethal dose of the H3N2 influenza virus. The efficacy of rAAV-CR9114 and rAAV-MEDI8852 against this influenza virus strain was lower, at 80 and 75%, respectively.